Viseon, Inc., an Irvine, Calif.-based closed medical device company, $18.0m Series B financing.
The round was co-led by Invus Opportunities, affiliates of Wexford Capital LP and HBM-MedFocus.
The company intends to use the funds for ongoing product development, worldwide regulatory approvals, clinical evaluations, manufacturing scale-up and commercialization efforts.
Founded in early 2017 as a spin-out from Rebound Therapeutics Corporation, and led by Jeffrey Valko, President and CEO, and Peter Davis, Chief Operating Officer, Viseon is a medical device company building out proprietary technology comprised of visualization and illumination technologies for use in Minimally Invasive Spine Surgery (MISS) procedures. The Viseon technologies can be adapted for a variety of MISS procedures including a wide range of cervical, thoracic and lumbar procedures, as a replacement where Surgical Microscopes and Endoscopes are routinely used today. They are also being adapted to more advanced lateral access MISS procedures, where visualization remains a challenge.
The disposable products developed by the company aim to reduce high capital equipment cost, OR footprint, maintenance and calibration expense, OR scheduling, reusable sterilization risks, procedural inefficiencies and user ergonomic burdens.
FinSMEs
25/02/2020